Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome (MDS)

    Stages patients with MDS.

    INSTRUCTIONS

    Use at the time of diagnosis, before starting treatment.

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients newly-diagnosed with myelodysplastic syndrome.

    • The IPSS-R categorizes patients into 1 of 5 groups, from very low risk to very high risk, based on risk of mortality and transformation to acute myeloid leukemia (AML).
    • This score is not dynamic and is meant to be used at the time of diagnosis only. That being said, the score does get higher with disease progression.
    • The IPSS-R has better discrimination and is more widely used over the original IPSS (see Evidence).
    • Data are based on untreated patients, represent statistical probabilities, and are not absolute.

    Can help determine whether to treat or observe, and what type of treatment, based on risk score.

    Very good: del(11q) or -Y
    0
    Good: normal karyotype, del(20q), del(5q), del(12p), or double including del(5q)
    +1
    Intermediate: +8, del(7q), i(17q), +19, or any other single or double independent clone
    +2
    Poor: -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), or complex (3 abnormalities)
    +3
    Very poor: complex >3 abnormalities
    +4
    ≤2
    0
    >2 to <5
    +1
    5 to 10
    +2
    >10
    +3
    ≥10 (≥100)
    0
    8 to <10 (80 to <100)
    +1
    <8 (<80)
    +1.5
    ≥100
    0
    50 to <100
    +0.5
    <50
    +1
    ≥0.8
    0
    <0.8
    +0.5

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Peter Greenberg

    About the Creator

    Peter Greenberg, MD, is professor emeritus of hematology at Stanford University. He is also director of the Stanford Myelodysplastic Syndrome (MDS) Center, coordinator of the International Working Group for Prognosis in MDS and chair of the National Comprehensive Cancer Network MDS Practice Guidelines Panel. Dr. Greenberg’s research focuses on evaluating molecular and genetic abnormalities in myelodysplastic syndromes.

    To view Dr. Peter Greenberg's publications, visit PubMed

    Are you Dr. Peter Greenberg? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    About the Creator
    Dr. Peter Greenberg
    Are you Dr. Peter Greenberg?
    Content Contributors